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Abstract
Introduction: Leptin is a peptide hormone with a role in bone metabolism and rheumatic diseases. The subchondral 
bone tissue plays a prominent role in the pathophysiology of osteoarthritis (OA), related to abnormal osteoblast (Ob) 
differentiation. Although leptin promotes the differentiation of Ob under normal conditions, a role for leptin in OA Ob 
has not been demonstrated. Here we determined if endogenous leptin produced by OA Ob could be responsible for 
the expression of the abnormal phenotypic biomarkers observed in OA Ob.
Methods: We prepared primary normal and OA Ob from subchondral bone of tibial plateaus removed for knee surgery 
of OA patients or at autopsy. We determined the production of leptin and of the long, biologically active, leptin 
receptors (OB-Rb) using reverse transcriptase-polymerase chain reaction, ELISA and Western blot analysis. We 
determined the effect of leptin on cell proliferation by BrdU incorporation and 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assays, and we determined by Western blot analysis phospho 42/44 MAPK (p42/44 
Erk1/2) and phospho p38 levels. We then determined the effect of the addition of exogenous leptin, leptin receptor 
antagonists, inhibitors of leptin signaling or siRNA techniques on the phenotypic features of OA Ob. Phenotypic 
features of Ob were determined by measuring alkaline phosphatase activity (ALP), osteocalcin release (OC), collagen 
type 1 production (CICP) and of Transforming Growth Factor-β1 (TGF-β1).
Results: Leptin expression was increased approximately five-fold and protein levels approximately two-fold in OA Ob 
compared to normal. Leptin stimulated its own expression and the expression of OB-Rb in OA Ob. Leptin dose-
dependently stimulated cell proliferation of OA Ob and also increased phosphorylated p42/44 Erk1/2 and p38 levels. 
Inactivating antibodies against leptin reduced ALP, OC, CICP and TGF-β1 levels in OA Ob. Tyrphostin (AG490) and 
piceatannol (Pce), inhibitors of leptin signaling, reproduced this effect. Inhibition of endogenous leptin levels using 
siRNA for leptin or inhibiting leptin signaling using siRNA for OB-Rb expression both reduced ALP and OC about 60%. 
Exogenous leptin addition stimulated ALP, yet this failed to further increase OC or CICP.
Conclusions: These results suggest that abnormal production of leptin by OA Ob could be responsible, in part, for the 
elevated levels of ALP, OC, collagen type 1 and TGF-β1 observed in these cells compared to normal. Leptin also 
stimulated cell proliferation, and Erk 1/2 and p38 signaling. Taken together, these data suggest leptin could contribute 
to abnormal osteoblast function in OA.
Introduction
Osteoarthritis is characterized by progressive articular carti-
lage loss, appositional new bone formation and sclerosis of
the subchondral trabeculae and growth plate, formation of
osteophytes, and an imbalance between loss of cartilage,
due to matrix degradation, and an attempt to repair this
matrix [1,2]. Synovitis is often observed and is considered
to be secondary to the changes in hard tissues within the
joint. Despite major progress in the last few years, we still
have a lot to learn about the etiology, pathogenesis and pro-
gression of this disease [3]. The slowly progressive and
multifactorial nature of the disease, its cyclical course,
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where a period of active disease is followed by a period of
remission, have limited our comprehension of OA. Risks
factors for this disease in humans include age, gender,
genetic predisposition, mechanical stress and/or joint
trauma, and obesity [3,4].
A relationship exists between obesity/fat mass and bone
mass, while the mechanisms responsible for this are still not
fully understood, and OA patients have a better preserved
bone mass [5,6], independently of body weight [7], than
healthy individuals. High body mass index (BMI) and
increased bone mineral density (BMD) suggest new bone
synthesis exceeds degradation in OA. In support of this
hypothesis, osteocalcin (a marker of bone formation) in
synovial fluid and serum osteopontin (a bone specific
matrix protein) were significantly higher in patients with
knee scan abnormalities [8]. Gevers and Dequeker showed
elevated serum osteocalcin levels in women with hand
osteoarthritis, and elevated osteocalcin in cortical bone
explants [9]. This group also reported that IGF-I and II, and
TGF-β levels are higher in samples of iliac crest bone of
patients with OA [10], at a site distant from weight bearing
joints, suggesting a generalized bone metabolic dysfunc-
tion. Our group showed that in vitro OA Ob produced
higher IGF-1 and TGF-β levels compared to normal
[11,12].
Leptin, the product of the obese (ob) gene, is a 16-kDa
secreted protein that is produced by white adipocytes and
placenta, and functions as an afferent signal to influence
energy homeostasis through effects on energy intake and
expenditure [13-15]. When leptin is mutated it results in
obesity in the ob/ob mouse [13]. It is now evident that lep-
tin is also expressed in osteoblasts [16]. Moreover, in addi-
tion to its effects on the central nervous system (CNS),
leptin acts through high affinity leptin receptors on cells in
peripheral tissues [17-19]. Leptin suppresses specific bio-
chemical processes contributing to lipid accumulation and
adipocyte differentiation [20]. The long, signaling-compe-
tent isoform of the leptin receptor (OB-Rb) shows high
expression peaks in the feeding centers of the hypothalamus
[21], consistent with leptin being the afferent signal inform-
ing the CNS of the body fat status. However, obese people
often have elevated leptin levels with limited effects of lep-
tin administration. This is likely due to desensitization, via
the saturable transport of leptin across the blood-brain bar-
rier and abnormalities at the level of OB-Rb activation and/
or signal transduction [22].
The primary role of leptin in metabolic homeostasis is to
provide to the hypothalamus the information on the amount
of body fat, thereby modulating central nervous system
functions that regulate food intake and energy balance
[23,24]. Solely via this neuroendocrine loop, leptin was
believed to control bone mass. For example, in obese chil-
dren, an increase in height velocity is concomitant with
acceleration of bone epiphyseal maturation of the growth
plate [25] and leptin levels are increased and correlate posi-
tively with fat mass [26]. Hence, leptin was believed to be
the neuroendocrine link between fat and bone mass [27-29].
Indeed, leptin increases the release of osteocalcin, an osteo-
blast-specific protein, via a hypothalamic relay [30]. More-
over, in fetal mice leptin increases growth of primary
ossification centers [31], and leptin modulates osteogenesis
[29,32,33]. Recent data also indicate that locally produced
leptin may be more important than circulating leptin in reg-
ulation of bone metabolism [16,17,29], while body mass
influences cortical bone mass independent of leptin signal-
ing [34]. Leptin administration to a natural leptin knockout
mouse model (ob/ob) increases bone mineral density
(BMD) as well as limb length [35]. This positive effect on
bone turnover may be linked to its effect on both IL-6 and
the osteoprotegerin (OPG)/RANKL system [33,36]. Leptin
enhances metabolic markers in osteoblasts namely alkaline
phosphatase activity, osteocalcin, Coll 1 α1 chains, Insulin-
like Growth factor-1 and Transforming Growth Factor-β1
(TGF-β1) levels by approximately 40% [36], parameters
which we previously showed to be all increased in OA Ob
compared to normal [11,12].
Leptin was found by immunohistochemistry in OA carti-
lage and in osteophytes, while few staining could be found
in normal tissues [37], and leptin levels correlated with car-
tilage destruction. Moreover, differential expression of lep-
tin and leptin receptor Ob-Rb was also recently uncovered
between minimally affected and advanced OA cartilage
[38]. Synovial fluid leptin levels also correlate with the
severity of OA [39]. However, there are at present no key
data on the presence or role of leptin in osteoblasts from the
subchondral bone tissue of normal or OA individuals.
Hence, this study was aimed at: i) identifying the source of
leptin in OA bone tissue by measuring leptin expression
and release by normal and OA Ob; ii) determining if exoge-
nous leptin could alter cell proliferation of OA Ob; and iii)
evaluating if local leptin production is responsible for
abnormal production of phenotypic markers in OA Ob.
Materials and methods
Patients and clinical parameters
Tibial plateaus were dissected away from the remaining
cartilage and trabecular bone under sterile conditions from
OA patients who had undergone total knee replacement sur-
gery as previously described [11,12,40]. A total of 64
patients (aged 71.5 ± 9.9 years) classified as having OA
according to the recognized clinical criteria of the Ameri-
can College of Rheumatology were included in this study
[41]. OA grade ranged from moderate to severe in these
patients. None of the patients had received medication that
would interfere with bone metabolism, including corticos-
teroids, for six months before surgery. A total of 16 sub-
chondral bone specimens of tibial plateaus from normal
individuals (aged 62.2 ± 18.9 years) were collected atMutabaruka et al. Arthritis Research & Therapy 2010, 12:R20
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autopsy within 12 h of death. These were used following
the establishment that they had not been on any medication
that could interfere with bone metabolism or had any bone
metabolic disease. Individuals showing abnormal cartilage
macroscopic changes and/or subchondral bone plate sclero-
sis were not included in the normal group. All human mate-
rials were acquired following a signed agreement by
patients undergoing knee surgery or their relatives for the
specimens collected at autopsy following the Centre Hospi-
talier de l'Université de Montréal (CHUM) ethical commit-
tee guidelines.
Preparation of primary subchondral bone cell culture
Isolation of subchondral bone plate and the cell cultures
were prepared as we recently described [42]. At confluence,
cells were passaged once at 25,000 cells/cm2 and grown for
five days in HamF12/DMEM media (Sigma-Aldrich,
Oakville, Ontario, Canada) containing 10% FBS before
specific assays. These cells were incubated with the same
media containing 0.5% FBS. After 24 hours of precondi-
tioning, cells were incubated for either an additional 48
hours in HamF12/DMEM media containing 0.5% FBS and
the indicated treatments for the determination of phenotypic
markers, or they were incubated for an additional 24 hours
in the same media in presence or absence of increasing
doses of leptin and the indicated treatments for the determi-
nation of the expression of leption or OB-Rb, or they were
incubated for 15 minutes with increasing doses of leptin in
preparation for Western blot analysis of p42/44 and p38.
For the determiniation of phenotypic markers, cells were
either treated with 1 μg/ml recombinant human leptin
(rhleptin, Calbiochem, San Diego, California, USA), 10 μg/
ml recombinant human leptin R/Fc chimera (R&D Sys-
tems, Minneapolis, MN, USA) that neutralizes the activity
of rhleptin, 100 μM Tyrphostin (AG490, Sigma-Aldrich),
75 μM piceatannol (Pce, Sigma-Aldrich), or the vehicle.
Supernatants were collected at the end of the incubation and
kept at -80°C prior to assays. Cells were either prepared for
SDS-PAGE separation or RT-PCR experiments. Cells pre-
pared for SDS-PAGE separation were lysed with RIPA buf-
fer (50 mM Tris HCl pH 7.4, 1% NP-40, 0.5% Na-
deoxicholate, 0.1% SDS, 150 mM NaCl with the following
inhibitors: 10 μg/ml aprotinin, 10 μg/ml leupeptin, 10 μg/ml
pepstatin, 10 μg/ml O-phenatroline, 1 mM Na-orthovana-
date, 1 mM DTT), and kept at -80°C prior to assays. Protein
determination was performed by the bicinchoninic acid
method [43].
Phenotypic characterization of human subchondral Ob cell 
cultures
Phenotypic features of Ob were determined by evaluating
1,25(OH)2D3-dependent (50 nM) alkaline phosphatase
activity and osteocalcin release, and by measuring the
release of the carboxy-terminal propeptide of collagen type
1 (CICP) in cells treated or not for their last 48 hours of cul-
ture with recombinant human leptin R/Fc chimera to neu-
tralize the activity of leptin, 100 μM tyrphostin (AG490) or
75 μM piceatannol (Pce), inhibitors of leptin signaling, or
with siRNA directed against leptin or OB-Rb (see below).
Alkaline phosphatase activity was determined on cell ali-
quots by substrate hydrolysis using p-nitrophenylphosphate
(PNPP), and osteocalcin release was determined in cell
supernatants using an EIA as previously described [11,12].
CICP was determined using a selective ELISA (Quidel
Corporation, Cedarlane, Hornby, Ontario, Canada) in con-
ditioned media from confluent OA Ob incubated in
HAMF12/DMEM media containing 0.5% bovine serum
albumine (BSA). CICP release was then reported as ng per
cellular proteins. Transforming growth factor-β1 (TGF-β1)
was measured in supernatants using a highly specific Quan-
tikine ELISA assay from R&D Systems (Minneapolis, MN,
USA). The sensitivity of the assay is 7 pg/ml and is a very
specific assay that does not cross react with related cytok-
ines/growth factors when tested at saturating concentra-
tions. Cellular proliferation was assessed using two
complementary approaches: the BrdU cell proliferation
assay as described in the system's manual from Calbiochem
(San Diego, California, USA) and MTT assay as described
by Zhao et al[44]. Cells were plated at 10,000 cells/cm2 in
96-well plates in Ham F12/DMEM media containing 10%
FBS. After overnight attachment, cells were fed Ham F12/
DMEM media containing 0.5% FBS for 24 hours prior to
stimulation with or without increasing doses of recombi-
nant human leptin as indicated for another 24 hours of incu-
bation.
RT-PCR assays
For RT-PCR assays, total cellular RNA from normal and
OA Ob was extracted with the TRIzol™ reagent (Invitro-
gen, Burlington, Ontario, Canada) according to the manu-
facturer's specifications and treated with the RNA-free™
Dnase Treatment and Removal kit (Ambion, Austin, TX,
USA) to ensure complete removal of chromosomal DNA.
The RNA was quantitated using the RiboGreen RNA quan-
tification kit (Molecular Probes, Eugene, OR, USA). The
RT reactions were primed with random hexamers with 1 μg
of total RNA in a 100 μl final reaction volume followed by
PCR amplification as previously described [40] using 20
pmol of each specific PCR primers (see below). The ampli-
fication of all mRNA species was performed separately
from GAPDH mRNA amplification to avoid substrate
depletion. After amplification, DNA was analyzed on an
agarose gel and visualized by ultraviolet detection.
Real-time quantification of leptin and GAPDH mRNA
was performed in the GeneAmp 5700 Sequence Detection
System (Applied Biosystems, Foster City, CA, USA) with
the 2× Quantitect SYBR Green PCR Master Mix (Qiagen,
Missisauga, Ontario, Canada) used according to the manu-Mutabaruka et al. Arthritis Research & Therapy 2010, 12:R20
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facturer's specifications. Primers used were: 5'-GGCTTTG-
GCCCTATCTTTTC-3' (sense) and 5'-
GGATAAGGTCAGGATGGGGT-3' (antisense) for Lep1;
5'-CCTCATCAAGACAATTGTCACC-3' (sense) and 5'-
CAGCATGTCCTGCAGAGACC-3'  (antisense) for Lep2;
5'-GCCAGAGACAACCCTTTGTTAAA-3' (sense) and 5'-
TGGAGAACTCTGATGTCCGTGAA-3' (antisense) for
OB-Rb; 5'-CAGAACATCATCCCTGCCTCT-3' (sense)
and 5'-GCTTGACAAAGTGGTCGTTGAG-3' (antisense)
for GAPDH. Amplicons were 197, 376, 417 and 319 bp,
respectively. In brief, 100 ng of the cDNA obtained from
the RT reactions were amplified in a total volume of 50 μl
consisting of 1× Master mix, uracil-N-glycosylase (UNG,
0.5 Unit, Epicentre Technologies, Madison, WI, USA) and
the gene-specific primers which were added at a final con-
centration of 200 nM. The tubes were first incubated for
two minutes at 50°C (UNG reaction), then at 95°C for 15
minutes (UNG inactivation and polymerase activation) fol-
lowed by 40 cycles consisting each of denaturation (94°C
for 15 seconds), annealing (60°C for 30 seconds), extension
(72°C for 30 seconds) and data acquisition (77°C for 15
seconds) steps. The data were collected and processed with
the GeneAmp 5700 SDS software and given as threshold
cycles (Ct), corresponding to the PCR cycle at which an
increase in reporter fluorescence above baseline signal can
first be detected. When comparing normal and OA basal
expression levels, the Ct were converted to the number of
molecules and the values for each sample calculated as the
ratio of the number of molecules of the target gene/number
of molecules of GAPDH.
Inhibition of leptin and OB-Rb expression using siRNA
We used a siRNA technique to transiently inhibit leptin or
OB-Rb expression in OA Ob. SiRNA were obtained from
Dharmacon (Lafayette, CO, USA) and we followed the
manufacturer's directions for their preparation. Briefly, OA
Ob were split at 100,000 cells/ml. Leptin or OB-Rb siRNA
(a set of four different siRNA per gene) or scramble RNA
(basal condition) was added to OA Ob at a final concentra-
tion of 100 ng/ml with 6 μl Hi-perfect (Quiagen, Missi-
sauga, ON, Canada) per 100 μl total volume in BGJb media
without serum for one hour on Day 0 and Day 3. Cells were
then fed BGJb media with 10% FBS containing 50 nM
1,25(OH)2D3 until Day 7, with media changes every two
days. Cells were harvested in either ALPase buffer to per-
form ALP and protein determination or in TRIzol to pre-
pare for RT-PCR to detect changes in leptin and OB-Rb
levels. Supernatants were kept for the determination of
osteocalcin.
Western immunoblotting
The cell extracts were loaded on polyacrylamide gels and
separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) under reducing condition
[45]. Loading of the protein was adjusted according to the
cellular protein concentration of each specimen. The pro-
teins were then electrophoretically transferred onto Polyvi-
nylidene Fluoride (PVDF) membranes (Boehringer
Mannheim, Penzberg, Germany), and immunoblotting was
performed as described in the ECL Plus Western blotting
detection system's manual (Amersham Pharmacia Biotech,
Piscataway, NJ, USA). Rabbit anti-leptin receptor at a dilu-
tion of 1:1,000 (Cedarlane, Hornby, Ontario, Canada), rab-
bit anti-human actin at a dilution of 1:10,000 (Sigma-
Aldrich), rabbit anti p42/44 at a dilution of 1:5,000 (Cell
Signaling Technology, Beverly, MA, USA), rabbit anti-
phosphorylated p42/44 (Thr202/Tyr204) at a dilution of
1:5,000 (Cell Signaling Technology), rabbit anti p38 at a
dilution of 1:2,000 (Cell Signaling Technology), and anti-
phosphorylated p38 at a dilution of 1:1,000 (Cell Signaling
Technology) as primary antibodies, and goat anti-rabbit IgG
as secondary antibodies at a dilution of 1:20,000 (Upstate
Biotechnology, Lake Placid, NY, USA) were used for the
assays.
Densitometry analysis of western blot films was per-
formed on a Macintosh Mac OS 9.1 computer using the
public domain NIH Image program developed at the U.S.
National Institutes of Health with the Scion Image 1.63 pro-
gram [46].
Evaluation of leptin production
Leptin was evaluated in Ob-conditioned media. Confluent
Ob were cultured for 48 h in HAMF12/DMEM media con-
taining 0.5% FBS. At the end of the incubation, their condi-
tioned-media were concentrated five-fold using Amicon
Ultra-4 filters (Ultracil-10 k, Millipore Corporation, Bed-
ford, MA, USA) with a cutoff of 10 kDa. Samples were
centrifuged at 1,000 g for 15 minutes at 4°C. The concen-
trated conditioned media were then tested for leptin using a
selective high sensitivity ELISA (R&D Systems). The sen-
sitivity of the assay was 7.8 pg/ml and the intra-assay preci-
sion is 3.2 ± 0.2%.
Statistical analysis
All quantitative data are expressed as mean ± SEM. Statisti-
cal analysis was performed by an ANOVA analysis of vari-
ance for dose-response experiments, followed by adequate
subtests when statistical significance was reached. A non
parametric Mann-Whitney U statistical test was performed
for all other experiments and P values < 0.05 were consid-
ered statistically significant.
Results
Expression and production of leptin in osteoblasts
We first questioned if human OA osteoblasts (Ob)
expressed leptin compared to normal Ob using real-time
RT-PCR with two different set of primers, one described by
Dumond et al[37] for rat samples and adapted to the humanMutabaruka et al. Arthritis Research & Therapy 2010, 12:R20
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sequence, and the other by Gordeladze et al[16] for primary
human osteoblasts. Using both sets of primers we detected
leptin expression in OA Ob (Figure 1A). We next evaluated
if OA Ob produced variable levels compared to normal Ob.
Using real-time RT-PCR we observed that OA Ob produced
about approximately five-fold more leptin mRNA than nor-
mal Ob using one set of primers (Figure 1B). Since leptin
has been shown to promote its own expression [47], we
next determined if this could be the case in OA Ob. Indeed,
leptin dose-dependently stimulated its own expression (Fig-
ure 1C), yet this was also the case for OB-Rb expression
(Figure 2B). As Ob expressed leptin, we next evaluated the
capacity of Ob to synthesize leptin. As shown in Figure 1D,
OA Ob released about approximately two-fold more leptin
than normal Ob under basal condition when measured using
a very selective ELISA.
Expression and production of leptin receptors in 
osteoblasts
In order to determine if OA Ob could respond to leptin, we
next evaluated the presence of the long, signaling compe-
tent, form of the leptin receptor (OB-Rb). As shown in Fig-
ure 2A using real-time RT-PCR, OA Ob expressed slightly
less OB-Rb than normal Ob although this did not reach sig-
nificance. Exogenous leptin at high concentrations signifi-
cantly stimulated OB-Rb expression in OA Ob (Figure 2B).
In addition, OB-Rb mRNA levels were increased by both
TGF-β1 and HGF in OA Ob (not illustrated), and this
increased expression was reflected at the protein level by
Western blot analysis (Figure 2C). Similar Western blot
results were obtained with OA chondrocytes (not illus-
trated).
Role of leptin in abnormal phenotypic features of 
ostearthritic osteoblasts
Since OA Ob expressed both leptin and leptin receptors, we
tested if these cells could respond to exogenous leptin and
we first determined the effect of leptin on cell proliferation.
Figure 3A and 3B show that leptin dose-dependently (1 ng/
ml to 10 μg/ml) stimulated cell proliferation and this effect
plateaued at 100 ng/ml leptin when assessing proliferation
using BrdU incorporation or MTT assay respectively. We
next evaluated if the effect of leptin on cell proliferation
was via the Erk 1/2 MAPK pathway as we previously
showed with insulin-like growth factor 1 [45]. Indeed, in
response to exogenous leptin, phospho p42/44 MAPK lev-
els rose (Figure 3C). This effect was again dose-dependent
and also plateaued around 100 ng/ml (Figure 3D). In addi-
tion, we evaluated the role of leptin on the p38 pathway.
Again, leptin dose-dependently stimulated phospho p38
levels (Figure 3E) and this effect was significant at doses as
low as 1 μg/ml (Figure 3F).
Leptin influences the synthesis of phenotypic markers
and inflammatory mediators in a number of cells and in par-
ticular can increase phenotypic markers in primary human
Ob [36]. Because OA Ob responded to exogenous leptin,
we then questioned if the endogenous elevated leptin pro-
duction observed in OA Ob could be responsible for the
abnormal phenotypic markers of these cells. Hence, we
measured alkaline phosphatase activity, osteocalcin release
and the production of CICP under basal condition and in the
presence leptin or of a recombinant human leptin R/Fc chi-
mera (anti-Rb) that neutralizes the activity of leptin. First,
in preliminary assays we tested if exogenous leptin, the
recombinant leptin R/Fc chimera or the antagonist of leptin
signaling AG490 would alter alkaline phosphatase activity
in normal Ob. Indeed, leptin addition to normal Ob stimu-
lated vitamin D3-dependent alkaline phosphatase activity,
however, neither anti-Rb nor AG490 had any effect on this
activity (Figure 4A), indicating no cytotoxic effects of these
treatments on normal Ob. Hence, we next tested their effect
on OA Ob and compared it to basal levels of these pheno-
typic markers in normal Ob run in parallel. Here, the inhibi-
tion of leptin signaling in OA Ob in response to 100 μM
AG490 or 75 μM Pce, selective inhibitors of leptin intracel-
lular signaling, reduced ALPase and CICP to values similar
to normal Ob (Figure 4B and 4D), whereas the effect of
these inhibitors on osteocalcin secretion could not be tested
since they interfered with the EIA method. These inhibitors
did not promote any significant cell death as assessed by
total protein content and cell count by trypan blue exclusion
(not illustrated). In addition, anti-Rb inhibited all these
activities in OA Ob (Figure 4B to 4D). We then questioned
if exogenous leptin could promote these activities. The
addition of exogenous leptin to OA Ob enhanced vitamin
D3-dependent alkaline phosphatase activity (Figure 4B) as
in normal Ob (Figure 4A), but it failed to further stimulate
osteocalcin release (Figure 4B) or collagen type 1 produc-
tion (Figure 4C) above their already elevated values in OA
Ob.
As another key feature of OA Ob that distinguishes them
from normal Ob is their enhanced production of TGF-β1
[12], and because leptin has been shown to stimulate TGF-
β1 synthesis in other cells, we evaluated if high levels of
TGF-β1 in OA Ob could be due to a response to endoge-
nous leptin via a paracrine/autocrine stimulation. As shown
in Figure 4E, TGF-β1 levels in OA Ob were elevated com-
pared to normal Ob and the presence of AG490 or Pce
reduced by approximately 50% and approximately 60% the
endogenous levels of TGF-β1 in OA Ob, reducing them to
near normal values.
Last, using siRNA techniques, we next evaluated if inhib-
iting leptin or OB-Rb would abrogate the response of OA
Ob to endogenous leptin production. Indeed, as shown in
Figure 5A, siRNA against leptin reduced alkaline phos-
phatase activity about 60% compared to a scrambled RNA.
A similar observation could be made for osteocalcin (Fig-
ure 5B). Likewise, inhibiting OB-Rb expression usingMutabaruka et al. Arthritis Research & Therapy 2010, 12:R20
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siRNA techniques also reduced ALP and OC about 60% in
OA Ob (Figure 5A and 5B). Figures 5C and 5D show that
specific siRNA inhibition reduced leptin and OB-Rb
expression 60 and 55% respectively in these cells compared
to a scrambled RNA.
Discussion
In recent years, a key role of leptin in OA has been pro-
posed, primarily based on the observation that human artic-
ular cartilage from OA patients showed elevated leptin
levels using immunohistochemistry [37,38]. Leptin was
previously known to be present in chondrocytes of the
growth plate in young animals [27] and in fetal mice [39]
yet this information was lacking in adult cartilage until
Dumond et al[37] and Simopoulou et al described differen-
tial expression of both leptin and leptin receptors between
normal and OA cartilage [38]. In the present study, we
show that subchondral osteoblasts also have high levels of
expression for leptin. Together with the study by Simopou-
lou et al[38], this could suggest that the presence of leptin
in articular cartilage could also be due, at least in part, to its
local production in subchondral bone tissue. Indeed, since
OA Ob expressed more leptin mRNA and produced more
leptin, this could explain the higher protein levels found in
Figure 1 Production of leptin in normal and OA osteoblasts. The expression of leptin was first determined by qPCR. Confluent osteoblasts (Ob) 
were lized in TRIzol and RNA extracted as described in Material and methods. RNA (1 μg) was reversed transcribed followed by qPCR amplification of 
100 ng cDNA using specific primers for leptin and GAPDH. The data were processed with the GeneAmp 5700 SDS software and given as threshold 
cycle (Ct), corresponding to the PCR cycle at which an increase in reporter fluorescence above baseline signal can first be detected. The Ct was con-
verted to the number of molecules and the values for each sample calculated as the ratio of the number of molecules of the target gene/number of 
molecules of GAPDH. A) Quantification of leptin mRNA using Lep1 and Lep2 primers. Results are given as the mean value of markers relative to GAPDH 
± SEM of n = 4 OA preparations. B) Quantification of leptin mRNA levels in normal and OA Ob using Lep1 primers. Results are the mean ± SEM of n = 
5 normal and n = 15 OA individual Ob preparations. C) OA Ob were exposed to increasing doses of leptin and lepin mRNA levels were determined 
using Lep1 primers. Results are the mean ± SEM of n = 4 preparations. The protein production of leptin was next detected using a very selective ELISA. 
Conditioned-media of confluent normal and OA Ob incubated in HAM's F12/DMEM media containing 0.5% FBS for their last 48 hours of culture were 
recuperated and stored at -80°C. D) Aliquots were taken to measure leptin using a very sensitive ELISA. Results are the mean ± SEM of n = 5 normal 
and n = 6 OA individual Ob preparations.
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OA cartilage compared to normal tissue [37] if leptin can
seep to the articular cartilage via either the enhanced micro-
circulation present in the subchondral bone plate and the
deep layer of the articular cartilage or via microcracks
[48,49].
Our study also provided contrasting data on the regula-
tion of leptin expression by OA Ob. We first tried to dem-
onstrate a possible link between elevated TGF-β1 and HGF
levels produced by OA Ob [12,50]. and the expression of
leptin by these cells. As previously showed for a number of
tissues [51], TGF-β1 reduced significantly the expression
of leptin mRNA by OA Ob (not illustrated). In contrast,
HGF was without any significant effect on leptin expres-
sion. Second, 1,25(OH)2D3 stimulated several fold leptin
expression by OA Ob. This is in sharp contrast to available
data with adipocytes [52] that show a powerful inhibition of
leptin expression in response to 1,25(OH)2D3. Hence, adi-
pocytes and Ob behave differently and this could be a cru-
cial step in OA Ob. Indeed, OA Ob show enhanced
responses to 1,25(OH)2D3  stimulation [11,40], and this
could possibly contribute to the enhanced expression of lep-
tin.
Inasmuch as leptin expression is enhanced and its endog-
enous production is elevated in OA Ob, this could explain
the slight reduction in OB-Rb expression in these cells
compared to normal due to the continuous exposure to lep-
tin. This reduction in OB-Rb expression was also paralleled
by a slight decrease of leptin receptors at the protein level
as detected by Western blot analysis. However, OA Ob
could still respond to an acute exogenous leptin stimulation
with an increase in OB-Rb expression. In addition, OB-Rb
production was stimulated by TGF-β1 and HGF in OA Ob,
and this would indicate that the receptors could still be reg-
ulated normally in these cells. Nonetheless, this reduction
in OB-Rb does not lead to a reduction of the response of
OA Ob to leptin as was demonstrated here. Indeed, OA Ob
responded to exogenous addition of leptin with an increase
in cell proliferation, phospho p42/44 MAPK, and in alka-
line phosphatase activity as was previously reported for pri-
mary human osteoblasts [36]. In addition, leptin also
stimulated phospho p38 levels in OA Ob in the present
study downstream to a stimulation of the JAK2/STAT3
pathway (not illustrated). A previous study indicated a
JAK/STAT dependent involvement of the p42/44 MAPK
and p38 kinase pathways in the chondrogenic ATDC5 cell
line in response to leptin stimulation [53]. In contrast, leptin
could not increase osteocalcin secretion nor CICP or TGF-
β1 levels in OA Ob. This could either indicate that alkaline
phosphatase is more sensitive to leptin stimulation than the
other markers or else that osteocalcin, CICP and TGF-β1
production are less sensitive to leptin in these cells. Con-
versely, blocking OB-Rb signaling with inactivating anti-
bodies reduced the production of alkaline phosphatase,
osteocalcin, and CICP in OA Ob. This is a key observation
since OA Ob show abnormal phenotypic features, namely
elevated alkaline phosphatase activity, osteocalcin release,
collagen type 1, IGF-1 and TGF-β1 production
[11,12,40,54], all features that can be increased in response
Figure 2 Production of leptin receptors (OB-Rb) in normal and OA 
osteoblasts. The expression of leptin receptors was first determined 
by qPCR. A) Confluent Ob were lized in TRIzol and RNA extracted as de-
scribed in Material and Methods. RNA was reversed transcribed fol-
lowed by PCR amplification of 100 ng cDNA as described in Figure 1 
using OB-Rb and GAPDH primers. Results are the mean ± SEM of n = 7 
normal and n = 19 OA Ob preparations, P < 0.004 vs normal and OA. B) 
OA Ob were incubated for 24 hours with increasing concentrations of 
exogenous leptin. Cells were then lyzed and used for PCR amplification 
of OB-Rb as in A. Results are the mean ± SEM of n = 6 OA Ob prepara-
tions. Second, the production of leptin receptors was determined by 
Western blot analysis. C) Confluent Ob were treated for 48 hours with 
or without 1,25(OH)2D3 (50 nM), leptin (100 ng/ml), TGF-β1 (10 ng/ml) 
or HGF (10 ng/ml). The cells were then lized in RIPA buffer prior to sep-
aration using SDS-PAGE and Western blotting using specific antibod-
ies to OB-Rb.
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t
Figure 3 Cellular proliferation and intracellular signaling of OA osteoblasts in response to leptin. OA osteoblasts were plated at 10,000 cells/
cm2 and allowed to attach overnight in HAM's F12/DMEM media containing 10% FBS. Cells were then treated with the same media with 0.5% FBS for 
24 hours prior to receiving increasing doses of leptin (10 ng/ml, 100 ng/ml, 1 mg/ml or 10 mg/ml) or the vehicle in the same media for another incu-
bation of 24 hours. Cell proliferation was assessed by the incorporation of BrdU or MTT assay. A) Incorporation of BrdU by OA Ob in response to leptin; 
B) Proliferation of OA Ob by MTT assay; C) Representative phospho p42/44 Western blot analysis in response to increasing doses of leptin in OA Ob. 
D) Determination of phospho p42/44 levels using the NIH Image program developed at the U.S. National Institutes of Health with the Scion Image 
1.63 program [46]. E) Representative phospho p38 Western blot analysis in response to increasing doses of leptin in OA Ob. F) Determination of phos-
pho p38 levels using the NIH Image program developed at the U.S. National Institutes of Health with the Scion Image 1.63 program [46]. Values are 
the mean ± SEM of at least four separate experiments; *P < 0.05, **P < 0.01.
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o
Figure 4 Modulation of alkaline phosphatase, osteocalcin and collagen type 1 in OA Ob by inactivating leptin signaling. Confluent normal 
and OA Ob were treated for their last two days of culture with either media alone containing 0.5% FBS with or without 1,25(OH)2D3 (50 nM) as per 
indicated for the individual markers. Cells were treated with either exogenous leptin, antibodies against leptin, tyrphostin (AG490, 100 μM) or Piceatan-
nol (Pce, 75 μM) for 30 minutes prior to the addition of 1,25(OH)2D3 except for CICP that was performed in the absence of 1,25(OH)2D3. At the end of 
the 48 h incubation, the supernatant was kept for osteocalcin and for collagen production, and cells were lyzed in ALPase buffer prior to measuring 
alkaline phosphatase activity by substrate hydrolysis. A) Results of alkaline phosphatase activity for normal OB; B) Results of alkaline phosphatase ac-
tivity for OA OB; C) Results of osteocalcin release by OA Ob; D) Results of CICP production; E) Confluent OA Ob were incubated in Ham's F12/DMEM 
media without serum and containing 1% ITS. Cells were treated with or without exogenous leptin, tyrphostin (AG490, 100 μM) or Piceatannol (Pce, 75 
μM) for their last 48 hours of culture. Results of TGF-β1 levels in supernatants are shown. The results are the mean ± SEM of n = 4 normal and n = 9 
OA Ob preparations.
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 leptin [36]. Last, tyrphostin and piceatannol, selective
inhibitors respectively of the JAK2/STAT3 and JAK1/
STAT3 pathways involved in leptin signaling [55], reduced
the activity of alkaline phosphatase, and the production of
collagen type 1 and TGF-β1 by OA Ob. Thus, these data
suggest first, that the abnormal features of OA Ob could be
related to their endogenous elevated production of leptin,
and second, that this response to leptin involves the JAK2/
STAT3 downstream MAPK targets, Erk1/2 and p38. Last,
we showed a reduction in alkaline phosphatase activity and
osteocalcin release by silencing leptin with siRNA or
silencing OB-Rb with siRNA in OA Ob. This again is
pointing toward a key role of endogenous leptin to regulate
these activities in OA Ob.
Inasmuch as leptin contributes to stimulate the production
of IGF-1 and TGF-β1 by human osteoblasts [36], our data
would also indicate that leptin is a key signal in OA
pathophysiology. Indeed, both growth factors have been
implicated in the initiation and/or progression of OA and
we previously showed that both growth factors were ele-
vated in in vitro subchondral osteoblasts isolated from OA
patients [12,56] Moreover, leptin can alter the signaling of
IGF-1 in a number of cell systems [57-59] and we previ-
ously reported that IGF-1 signaling is abnormal in OA Ob
[45]. We also previously showed that HGF is not produced
by chondrocytes but is produced in higher abundance by
OA Ob [50] whereas HGF can increase OB-Rb levels in
chondrocytes (not illustrated). Hence, the presence of ele-
Figure 5 Modulation of alkaline phosphatase and osteocalcin release in OA Ob by inactivating leptin or leptin signaling. OA Ob were treated 
with siRNA for either leptin or OB-Rb or a scrambled RNA as described in Material and methods. Cells were then used to determine alkaline phos-
phatase activity and osteocalcin release. A) Results of alkaline phosphatase activity in response to leptin or OB-Rb siRNA treatments. B) Results of os-
teocalcin release in response to leptin or OB-Rb siRNA treatments. C) Leptin expression in response to siRNA. D) OB-Rb expression in response to siRNA. 
Results are the mean ± SEM of n = 6 OA Ob preparations.
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vated levels of leptin [37,38] in OA cartilage, and of ele-
vated expression of OB-Rb [38,60] possibly due to elevated
HGF levels [50] derived from osteoblasts of the subchon-
dral bone plate, could therefore promote the response to
leptin in OA chondrocytes.
The failure of leptin to stimulate all markers of osteo-
blasts whereas inhibiting leptin signaling modified all
parameters is puzzling. However, an abnormal response to
leptin in OA Ob is likely and resembles what we previously
observed for the response to IGF-1. First, an increase in
phospho-PTP1B/Syp may be crucial for leptin signaling as
PTP1B/Syp controls STAT3 phosphorylation and its inter-
action with target genes, a key signaling pathway for leptin
[61]. Since increased hypothalamic PTP1B levels can con-
tribute to leptin resistance [62], our previous demonstration
that PTP1B/Syp levels and phosphorylation are increased in
OA Ob [45] suggests that OA Ob could actually be resistant
to some, yet not all, leptin signaling since leptin did
increase the phosphorylation of Erk1/2 and p38 in OA Ob
(our present data). Second, leptin promotes tyrosine phos-
phorylation of SHC proteins and the association of SHC
with Grb2 in human embryonic cells HEK 293 [63],
whereas we previously showed that Grb2 interaction with
IRS-1 and SHC is abnormal in OA Ob [45]. Third, leptin
can modulate its effects on human Ob via an inhibition of
apoptosis [36], and we observed a reduction in Bax-α to
Bcl2 expression in OA Ob compared to normal Ob [45] an
indication of reduced apoptosis. Indeed, leptin increases the
proliferation of human osteoblast-like SaOS-2 cells via
Erk1/2 [64], and we also showed that OA Ob have an
enhanced proliferation rate and increased phospho Erk 1/2
levels in response to leptin. Last, we showed that leptin
stimulates alkaline phosphatase activity in OA Ob yet failed
to stimulate any further osteocalcin release, collagen pro-
duction or TGF-β1 levels above their already elevated lev-
els compared to normal Ob, whereas inhibiting leptin
signaling clearly showed an inhibition of all these parame-
ters. Previous studies have shown that long term exposures
to leptin are needed to modify the expression of collagen
type 1, TGF-β1 and osteocalcin [36] whereas the inhibition
of collagen synthesis with the JAK inhibitor AG490 (tyr-
phostin) is rapid [65] similar to what we observed here.
Taken together, these data would suggest that a number of,
yet not all, signaling pathways are altered in OA Ob in
response to leptin. Conversely, partners of leptin signaling
may be abnormal in OA Ob and this may stem from the
possible abnormal cross-talk between the IGF-1 signaling,
already abnormal in OA Ob [45], and leptin signaling path-
ways in these cells. These hypotheses remain to be
explored.
Conclusions
This study indicates that OA Ob expressed and released
more leptin than normal. This elevated production of leptin
is responsible, at least in part, for the abnormally elevated
levels of biomarkers of OA Ob compared to normal, and to
elevated production of TGF-β1. Together, these data indi-
cate a key role of leptin in OA pathophysiology.
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